Roundtable on Translating Genomic-Based Research for Health 2010 Annual Report (2011) / Chapter Skim
Currently Skimming:
Roundtable on Translating Genomic-Based Research for Health: 2010 Annual Report
Roundtable on Translating Genomic-Based Research for Health: 2010 Annual Report
Pages 1-8
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 1... ...
Martha Turner, Ph.D., R.N., B.C., C.N.A.A. American Nurses Association Blue Cross and Blue Shield Association American Nurses Association different perspectives to meet and discuss complex issues of mutual concern in a neutral setting, the Roundtable fosters dialogue across sectors and institutions and fosters collaboration Blue Cross and Blue Shield Association Bruce Blumberg, M.D.
|
From page 2... ...
Topics which were discussed Over 4 million infants a year are screened Biological specimens stored by investigators from the identification of genes associated with disease processes to the development included impediments to bringing basic for serious or life-threatening treatable in industry and academia provide a significant of pharmacogenetic tests which can minimize adverse side effects and increase treatment research discoveries into clinical trials, disorders in the United States through the untapped resource of genetic and genomic efficacy. These discoveries reveal the significant potential for benefit from this rapidly bioethical considerations surrounding collection and testing of blood samples information that can be used to develop growing area of science -- however, the pathway from discovery to health benefit is still the translation of genomics, and funding shortly after birth.
|
From page 3... ...
Topics which were discussed Over 4 million infants a year are screened Biological specimens stored by investigators from the identification of genes associated with disease processes to the development included impediments to bringing basic for serious or life-threatening treatable in industry and academia provide a significant of pharmacogenetic tests which can minimize adverse side effects and increase treatment research discoveries into clinical trials, disorders in the United States through the untapped resource of genetic and genomic efficacy. These discoveries reveal the significant potential for benefit from this rapidly bioethical considerations surrounding collection and testing of blood samples information that can be used to develop growing area of science -- however, the pathway from discovery to health benefit is still the translation of genomics, and funding shortly after birth.
|
From page 4... ...
Topics which were discussed Over 4 million infants a year are screened Biological specimens stored by investigators from the identification of genes associated with disease processes to the development included impediments to bringing basic for serious or life-threatening treatable in industry and academia provide a significant of pharmacogenetic tests which can minimize adverse side effects and increase treatment research discoveries into clinical trials, disorders in the United States through the untapped resource of genetic and genomic efficacy. These discoveries reveal the significant potential for benefit from this rapidly bioethical considerations surrounding collection and testing of blood samples information that can be used to develop growing area of science -- however, the pathway from discovery to health benefit is still the translation of genomics, and funding shortly after birth.
|
From page 5... ...
Topics which were discussed Over 4 million infants a year are screened Biological specimens stored by investigators from the identification of genes associated with disease processes to the development included impediments to bringing basic for serious or life-threatening treatable in industry and academia provide a significant of pharmacogenetic tests which can minimize adverse side effects and increase treatment research discoveries into clinical trials, disorders in the United States through the untapped resource of genetic and genomic efficacy. These discoveries reveal the significant potential for benefit from this rapidly bioethical considerations surrounding collection and testing of blood samples information that can be used to develop growing area of science -- however, the pathway from discovery to health benefit is still the translation of genomics, and funding shortly after birth.
|
From page 6... ...
Martha Turner, Ph.D., R.N., B.C., C.N.A.A. American Nurses Association Blue Cross and Blue Shield Association American Nurses Association different perspectives to meet and discuss complex issues of mutual concern in a neutral setting, the Roundtable fosters dialogue across sectors and institutions and fosters collaboration Blue Cross and Blue Shield Association Bruce Blumberg, M.D.
|
From page 7... ...
Martha Turner, Ph.D., R.N., B.C., C.N.A.A. American Nurses Association Blue Cross and Blue Shield Association American Nurses Association different perspectives to meet and discuss complex issues of mutual concern in a neutral setting, the Roundtable fosters dialogue across sectors and institutions and fosters collaboration Blue Cross and Blue Shield Association Bruce Blumberg, M.D.
|
From page 8... ...
Martha Turner, Ph.D., R.N., B.C., C.N.A.A. American Nurses Association Blue Cross and Blue Shield Association American Nurses Association different perspectives to meet and discuss complex issues of mutual concern in a neutral setting, the Roundtable fosters dialogue across sectors and institutions and fosters collaboration Blue Cross and Blue Shield Association Bruce Blumberg, M.D.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.